Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cantargia, Audiocast with teleconference, Q3'24

By Inderes11/15/2024, 2:00 PM
Cantargia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Johan
00:01 - 17:12

Thanks a lot. It's with great pleasure. We're here to present our Q3 report from Cantargia. It's been an exciting period with a rich news flow. And if we quickly summarize the news flow during or after this period, we've seen that we made progress in both of our clinical programs, the Nadunolimab and CAN10 programs. Some of the material events have been that the FDA gave us clearance to start a leukemia study, which is also fully funded by a grant from the US Ministry of Defence. And we got the first results in the randomized phase 2 trial, more clearly defining when to expect. And it's going to be in the first half of 2025, so obviously something to look forward to later on. Uh, we presented new clinical data first at the ESMO Congress on Nadunolimab combination therapy after relapse on PD1 inhibitor therapy. And that shows some very exciting data points. And we'll go through that in a second. And we also conducted a number of clinical trials that were initiated in 2021. But due to changing market conditions, we altered our strategy and did not complete those clinical trials. But now that the results are ready, we can see that we have clear support in our ongoing strategies from those trials. Uh, the CAN10 program, then, is not in cancer. So now we're switching gears towards immunological or inflammatory diseases. And a lot of focus has been on the Phase 1 clinical trials, where we have made progress. For instance, the safety analysis has looked very good. And an independent committee recommended continuing to the multiple dosing phase, which then started in September. Uh, but we also had lots of positive results regarding biomarkers and pharmacodynamic effects in the phase one clinical trial. Again, this is something we'll go through, and we presented more results on CAN10 in diseases at the conference. And then uh, very importantly, obviously, based on all this progress, we are now committed to continue to develop both programs. And, we are now announcing a rights issue, which is obviously pending FDA approval, but we will go through that in a second as well. So, then to take you through our program. So, the CAN10 program is uh, it's a unique molecule, CAN10. It is designed to basically inhibit three different inflammatory and disease-promoting cytokine systems at the same time. So it's the IL1, IL33, and IL36 systems. And uh, the inhibition is very potent. It binds with picomolar affinity and has, as I said, shown very good effects on blocking cytokines, but also very good effects in various in vivo models of both inflammatory and fibrotic diseases. And the lead indication we're going through right now is a skin disease called Hidradenitis Suppurativa. It is quite common. It affects about 1% of the Western population, and it starts as inflammation in the hair follicles, which then further progresses into something called draining tunnels, which are on the inside of the skin and cause severe problems and pain. And these patients are treated with antibiotics or steroids in the early stages. And once they're not responding to those, an antibody therapy is used; nevertheless, only 50% of patients respond to those therapies, and in the end of the day, they will stop responding and the disease will progress to more serious stages. So we believe that this is truly a great opportunity for a compound like CAN10. And we are even more encouraged because there is clinical evidence suggesting that both IL-1 blockade and IL-36 blockade have an impact on the disease. So if we benchmark to the IL-36 receptor-blocking antibody Spesolimab from Boehringer Ingelheim, there has been a clear effect, as you can see up to the right on this slide, on the draining tunnels, which are a severe problem of this disease. Uh, but also if you look down to the right corner, you can see that there is an antibody called Lutikizumab from AbbVie, which is targeting another part of the disease-promoting cytokines. Meanwhile, this system has a good effect on the inflammatory part of the disease. So as CAN10 is blocking both IL-36 and IL-1, we believe that we have a truly unique opportunity to design something that works much better. And to simplify this, the IL-1 receptor blockade or the IL-1 cytokine blockade will block the inflammation as proved by AbbVie, and the IL-36 receptor blockade will have a strong effect on the draining tunnels and potentially a little bit more. More speculatively, the IL-33 blockade, which we have also built into CAN10, will block the itch component, which is also a serious part of HS. So we are super enthusiastic about taking this drug forward from Phase 1 and into Phase 2 in HS. And we believe that we're ready to do that during the second half of next year. Uh, so then quickly on what we've seen so far. So the CAN10 results previously presented to date are all from single-dose studies. Uh, and to summarize, we've observed very, very good safety results. So we have no safety signals, which is very encouraging. Uh, but we do see that the drug is biologically active. So if you look down to the left, you can see that the drug binds to two types of immune cells, which are driving diseases like monocytes and neutrophils. So basically, the higher the dose, the higher the number will be in the said cohort. And you can see that with increasing doses, we get increased binding. What's really interesting is that if you look to the right, when we analyze these immune cells in whole blood after treatment with CAN10, we can see that they are no longer responding to cytokines like IL-36. And again, it's dependent on the dosing. So the higher the dose we give, the better the effect we will have. So at the end of the day, we believe that we have a drug which is essentially turning off the inflammatory properties of these disease-promoting cells, and this is generating a lot of interest. So then moving into our second program, Nadunolimab. So IL1RAP, which is a target for both CAN10 and Nadunolimab, is overexpressed on a large number of solid tumors. And therefore, we believe that we have a unique opportunity to treat cancer as well. And IL1RAP is not only expressed on the cancer cells, but it's also found on immune cells and fibroblasts in the tumor microenvironment, and we are not going to do a deep dive into all the data we have. We have treated more than 300 patients so far, and we present the data from more than 200. But some of the strongest data has been observed in pancreatic cancer. And here, we treated patients in the first line setting. So basically, patients that are newly diagnosed with pancreatic cancer, which has spread in the body, have a poor prognosis and are typically treated with chemotherapy like gemcitabine and Abraxane. And what we do see is that in the total population, we have a very positive effect. But we've conducted a more sophisticated analysis to determine if there are higher or lower levels of IL1RAP in the tumor tissue. And interestingly, it's really the patients with the high values or levels of IL1RAP which are driving the response here, which you can see both to the right in the waterfalls, where, let's say, the best decreases in tumor size are observed in the IL1RAP high group. And also to the left where you look at the survival, which is about 14.2 months, versus 10.6 months in the high IL1RAP group versus the low group. And interestingly, IL1RAP is linked to worse prognosis. And it's also linked to specific KRAS mutations which are supposed to drive the disease. So again, this is a really, really important finding. And we're now going forward into randomized trials. And the exact design is not ready yet. But it's going to be a Phase 2 and Phase 3 trial where we will include the diagnostic method to really select the patients with high IL1RAP, to maximize the chances of a positive result and minimize the risk in the high IL1RAP group in the first-line setting. We estimate that around 60% of the patients, so it's a significant group where we can make a difference. Another exciting observation is that Nadunolimab, when added to chemotherapy, shows significant results. With chemotherapy, you have to be really cautious because it is really on the borderline. Of what the patient can cope with. And interestingly, we have seen when we add Nadunolimab. That we actually increase tolerability. One of the side effects of chemotherapy is neuropathy. Neuropathy. And we see that when we add Nadunolimab, the patients experience less neuropathy than you would expect from historical chemotherapy controls. And we also see that there is a dose response here. So, the higher dose levels of Nadunolimab, the more pronounced this effect is. And you can see that to the right. And this fits extremely well with our mechanism of action, where immune cells that accumulate in the nerves are contributing to this really, really horrible side effect. And we are very excited to continue to do this. And we have not only seen these effects with Abraxane in the study, but we have also seen them later on with oxaliplatin in the later trials that were recently presented, but also with the next generation chemotherapy, which is antibody-drug conjugates. We have good reasons to believe that we can have similar effects. So, this is definitely a finding with very high potential future value. And finally, the data concerning lung cancer. So this is obviously a busy slide. But the key point here is that patients who have been treated with the PD1 inhibitor. So these are lung cancer patients treated with PD-1 inhibitors, which is really standard first-line therapy. They experience changes in the tumor microenvironment that make them more likely to be sensitive to Nadunolimab. And you can see on the right, when you examine all these tumor tissues, that these patients have a significantly higher number of IL1RAP-containing immune cells in the tumor microenvironment. And they also have lots of other immune cells which should react positively to Nadunolimab treatment. And the clinical results we then observed in this group are very encouraging. With more than a 90% response rate as well as 26 months overall survival in the non-squamous second-line non-small cell lung cancer group. So clearly, this result is creating interest and gives us a way forward in the lung cancer area as well. So in summary, Nadunolimab. So we treated more than 300 patients. We have a pretty solid database with robust data, and we are starting to see more and more data that allows us to identify the subgroups both in pancreatic cancer and lung cancer, which are really the key patients to target. And we are developing diagnostic tests to be used. And we have also seen that the safety is good, and we actually counteract neuropathy. So with that, we're in a good position. But we're also generating more data, both in triple-negative breast cancer and leukemia through the ongoing and upcoming trials. So it's a very exciting future for this program as well. So by that, I'm finishing off with what you as an investor can expect from milestones. So in pancreatic cancer, there is the upcoming trial in the high IL1RAP subgroup starting the second half of next year. And in triple-negative breast cancer, we expect the first randomized data set with Nadunolimab, and top-line data will be presented later on during H1 next year. Uh, the leukemia trial. We hope to include the first patients during Q4 this year, and it's in collaboration with MD Anderson, as we previously discussed. And then the CAN10 program where recruitment is ongoing for the MAD phases. We expect the Phase 1 data to come sequentially during H1, with final data during Q2 next year, and then starting with Phase 2 during the second half of 2025. So by that, I've covered where we are with the products and what's in the near future, and hand over to Patrick to go through the finances as well as the upcoming rights issue.

Patrick
17:14 - 21:53

Thank you, Johan, for that. And I'm going to present a few highlights. You can see the most important numbers from our recently issued financial statements presented here, and I'm not going to read the numbers. You can do that as well. Good. As good as I do. But I want to give you a few comments on what you see here in the numbers. And I'll focus on the year to date. And maybe just to repeat what we've said in a few reports. Now, continuously, we are at a lower level of activity and spending compared to previous periods. Years. And you can see that in the year-to-date number for our R&D, we are more than 40% lower than the previous period. Than the previous period. And that is the result of having now formally closed and reported. Uh, CAN404, CESTA4, and KAPA4 are actively recruiting. Um, I wouldn't say only, but I'll say it anyway. So, TRI4 and CAN10 Phase 1. Very important studies. But overall, the activity is lower in that area. And we're also, as we have reported previously, well-supplied with some drug substance. So, we have not made any new investments in CMC this year. So we are disciplined in the activities that we approve and start, making sure that they drive the projects forward and generate value for the company and the investors. And the same discipline applies in G&A, and I, we reported in combination with Ohio, and just, uh, we can't ignore it. But Ohio is always basically, um, about things we can't impact, such as currency fluctuations. But if we look at the DNA, so our general and administrative expenses, we have reduced that by 5% year on year. And, um, that is again a result of scrutinizing what we do and making sure that we don't do anything unnecessary. Um, overall, our reported loss, just to mention one number, is 122 million for the year to date, which was then positively impacted by financial items of over 5 million Swedish. And that is significantly less than last year. And that is because we simply have less capital to invest and earn interest from. Um, and that is also what we see here. We have a cash balance now at the end of September of approximately 60 million. Um, and that is also um, the main reason why we have, um, well, the board has, uh, asked our shareholders to approve a rights issue. We expect, um, well, if fully subscribed, we expect to receive 170 million in gross proceeds, and 120 million in case of subscription up to the guaranteed level. And that will suffice to do the activities needed to bring the projects forward until the middle or end of the first half of 2026 if fully subscribed. And, um, a little bit into 2026 if subscribed in accordance with the guaranteed amount. And that is all from me and us. And I believe we open up for questions.

Operator
21:57 - 22:15

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
22:18 - 22:33

Good afternoon. I have a few questions, starting with TRY. Could you specify what data points you will disclose in H1 and what new data in H2 2025?

Johan
22:36 - 23:28

Yes, of course. Uh, so, uh, the plan. So for Try, we expect the last patient to be enrolled during Q1 next year. Uh, and uh, the plan is to disclose response data on all patients after two CT scans, which will be three months later. So the initial presentations will focus on response rates and safety in H1. And then, obviously, we will be ready for PFS and potentially OS during H2. We will also be ready to advance with additional analyses as needed. Okay, good. More. We will also be ready to perform subgroup analysis as well during H2. Ready to go into subgroup analysis as well during H2.

Richard Romanus
23:31 - 23:49

And that will suffice to do the activities that are needed to bring the projects forward until the middle or end of the first half of 2026 if fully subscribed. Um, then I had some questions about the second line. Um, lung cancer, would you say that, from your experience, IL1RAP is upregulated after first-line treatment with a checkpoint inhibitor?

Johan
23:52 - 24:27

So, uh, IL1RAP seems to be upregulated on immune cells in the tumor microenvironment after checkpoint inhibitors. And the hypothesis here is that it's because when you get resistant to checkpoint inhibitors, one mechanism is through the infiltration of myeloid-derived suppressor cells, which are known to overexpress IL1RAP.

Richard Romanus
24:34 - 24:46

And that will suffice to do the activities needed to bring the projects forward until the middle or end of the first half of 2026 if fully subscribed. Interesting. And another question, also on lung cancer. What is the unmet need for the second line after using checkpoint inhibitors in the first line?

Johan
24:49 - 25:39

Yeah. What should I say? I think the second line treatment after using checkpoint inhibitors in the first line is crucial. So, typically, the first-line treatment would be Keytruda and platinum-based chemotherapy unless you administer it sequentially. But for the majority of patients, that's the treatment. And in the second line, there are very few treatment alternatives. So I think often you will find docetaxel being used. There is some development of ADCs. There is some development of KRAS inhibitors in this space, which is going to be perhaps more fragmented. But these patients have very few treatment alternatives. And still, it's a huge group of patients.

Richard Romanus
25:45 - 25:54

Yeah. Good. Um. What can you say about the funding for the phase two study of CAN10?

Johan
25:57 - 26:52

The CAN10 trial is in phase two, but the design is not yet ready. It will be designed together with the KOLs and based on regulatory advice from the FDA. But in this fundraising, we have not included the Phase 2 costs. We are also in a number of ongoing discussions right now on, let's say, next steps, both for Nadunolimab and CAN10. And I think we need to go through all these discussions, materialize, or be more concrete before deciding on where to go.

Unknown 1
26:54 - 26:55

What is the unmet need for the second line after using checkpoint inhibitors in the first line?

Richard Romanus
26:55 - 27:12

Um, last question. Would it be correct to characterize the diagnostic tests you're developing as being for Nadunolimab. But you mentioned you could use it for CAN10 as well as a companion diagnostic.

Johan
27:14 - 28:08

So yes, I think in the end of the day we will probably go that way towards some kind of companion diagnostic. Uh, but there, there are several aspects, I think this type of assay is being developed for pancreatic cancer, but we can most likely also adapt it for, for other types of diseases. But we believe that this type of test will generate huge value for the whole platform. Both Nadunolimab and CAN10, as well as potential clinical programs coming in the future.

Richard Romanus
28:13 - 28:15

Well, that's all for me.

Operator
28:21 - 28:26

The next question comes from Luisa Morgado from Van Lanschot. Kempen. Please go ahead.

Luisa Morgado
28:29 - 28:53

Hi, team. Thank you for taking my questions. Maybe the first one in terms of the pancreatic cancer program, you mentioned that this might be pursued under the form of a phase two or phase three. Could you elaborate a bit more on what this depends on? And, um, when will we see the first results from this trial?

Johan
28:55 - 30:40

Yeah. So, what we're doing. Right. So we're executing a series of sequential steps here. So the first step is to advance the diagnostic test a little bit further. So we're ready to have those discussions with the regulatory authorities. And once we have had those discussions and have their feedback, we will then be ready to suggest a trial design, which could be phase two or phase three. And there are various pros and cons around this. And also to take into account the context of Project Optimus here. So once we have advanced in our discussions with both Key Opinion Leaders (KOLs) and regulatory authorities. Et cetera. We will disclose a little bit more on the design. And that will have an effect on the timelines. But clearly, if we go for a smaller phase two, you should expect results relatively quickly afterwards, let's say a year or so. If we go for a more phase three type of design, it obviously depends on what the endpoint for a phase three trial might be. But if we're talking about, let's say, a fully randomized phase three trial with a survival endpoint, it's probably going to take two and a half to three years to get results.

Luisa Morgado
30:44 - 31:02

Kempen. Makes sense. Thank you. And in terms of if you are assuming that the rights issue goes through, what does the new cash runway cover in terms of all the programs that you have now?

Johan
31:04 - 31:07

I don't know, Patrick, should you take this question?

Patrick
31:07 - 32:03

Um, yeah. So it's basically, um, the whole idea is to make sure that we are ready to start the phase two program in OS, not having the clinical trial funded, but be ready. Um, so it will cover the necessary preparations to achieve that. Um, and it basically covers the activities that you just discussed about, um, the PDAC and the diagnostic, getting that validated and ready to be used and keeping the company, uh, running. In the case of full subscription, we expect to keep the business financed until the middle of 2026. Um, so did that answer your question, or do you want me to elaborate?

Luisa Morgado
32:03 - 32:15

Yes, yes, yes. No, no, it does. Answer. And maybe a follow-up question for you, Patrick. In terms of the expenses for the remainder of the year and also next year, what can we expect here?

Patrick
32:17 - 32:37

Uh, are we? The burn rate that we currently have is likely what we will maintain. But, um, exactly how it will fluctuate quarter by quarter. It's nothing that we disclose, but basically we are at the burn level that you can expect.

Unknown 1
32:40 - 32:40

Oh, yeah.

Luisa Morgado
32:40 - 32:43

Um, so it will cover those preparations to do that, to get there. That's quite helpful. Um, so it will cover those preparations, um, to do that, to get there. That's all from my side.

Operator
32:49 - 33:12

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Unknown 2
33:13 - 33:28

The first written question is how important is the newly announced biomarker strategy for getting a specialist or partner on board, and what do you expect will happen when that strategy is implemented in terms of these discussions?

Johan
33:31 - 34:34

So, clearly, I think everything within cancer treatment that can be narrowed down to patients most likely to respond will be valued very highly, regardless of whether it concerns potential partners, investors, clinicians, or patients. So even if you have pancreatic cancer, one pancreatic cancer is not the same as the second one, so having this type of diagnostic tool, it's going to be very, very valuable and very much appreciated. One pancreatic cancer is not the same as another, so having this type of diagnostic tool is going to be very, very valuable and very much appreciated. And then if we can adapt it to work in several different cancer forms or even outside, it's going to be even more of strategic value. So I think it's, what you should say, really important in our ongoing discussions.

Unknown 2
34:36 - 34:44

Thank you. And the next question is regarding when you think that the company will transition into a commercial phase.

Johan
34:45 - 35:37

Yeah, that's a great question. And so, if we assume that pancreatic cancer is the most advanced opportunity, and if we are in a position to start a phase three trial, one of the opportunities would be for the second half of next year. In this type of subgroup, we will have results in perhaps two and a half to three years. And then, obviously, we hope to get the commercial activities starting as soon as possible afterward. So, we're talking somewhere around 2028. Unless there is a way to get some kind of accelerated approval before that, if the data are really, really good in the phase three trial.

Unknown 2
35:39 - 35:50

Thank you. And the next question is regarding PDAC and what percentage of KRAS G12D patients are upregulated for IL1RAP.

Johan
35:53 - 36:44

So we don't have the exact numbers. So what we know is that in all comers, pancreatic cancer, or at least first line metastatic, 60% overexpress IL1RAP. We've done lots of analysis on the RNA level to see if there are correlations between G12D or other KRAS mutations in high IL1RAP. Uh, and we can clearly see that there is this type of correlation. So my answer is that it's going to be much higher than 60%. But, uh, the exact number is not known yet, but we're working on it.

Unknown 2
36:45 - 36:54

Thank you. And then, another question is, what happened to your participation in the Pancan Precision Promise study?

Johan
36:55 - 38:12

Yeah. So the original plan for pancreatic cancer development was to work with the US group called the Pancreatic Cancer Action Network, or Pancan, who already had a phase three registration trial running in pancreatic cancer. And during that trial, there have also been new regulatory guidelines around dose selection. And it was not possible to adapt the new guidelines with this already approved protocol for us. So, so we had to go a different route here. Uh, which in a way is sad, but also has become an opportunity because it has given us the time to develop these diagnostic tests and increase the likelihood of success here by selecting the best responders to Nadunolimab.

Unknown 2
38:15 - 38:28

Thank you. Um, another question is why do you think that the Nadunolimab is not talked about as a bispecific killer cell engager.

Johan
38:31 - 38:44

Indeed. Yeah. I have, uh, no good answer. Why are we not talking about this as a bio care? But we probably could. And so if we assume that pancreatic cancer is the most advanced opportunity, and if we are in a position to start a phase three trial, one of the opportunities would be for the second half of next year.

Unknown 2
38:46 - 38:56

Thank you. Uh, and, uh, getting back to the CAN10 project, can you elaborate a bit more on the readout timeline for that project?

Johan
38:57 - 40:07

So, the phase 1 trial is going to have a final readout during H1. But I assume the question relates to phase two. So, uh, we plan to start a phase two trial in HHS during the second half of 2025. A little bit depends on which patients we include, how many patients we're recruiting, and exactly when the primary analysis is made. We're probably talking late 2026 or early 2027 for the final readout. Uh, if we're going for other indications, it would be great to do smaller trials as well. Outside H.S. We may get some kind of phase two results. Earlier during 2026, but that remains to be seen. The highest priority is the OS trial. OS trial.

Unknown 2
40:09 - 40:15

Uh, and, uh, getting back to the CAN10, uh, project, can you elaborate a bit more on the readout timeline for that project. And can you elaborate a bit on how the diagnostic test will work practically. Will work practically.

Johan
40:17 - 41:05

Yeah. So, uh, in the case of pancreatic cancer, if. If you're newly diagnosed with pancreatic cancer, you would have a biopsy. Available where the diagnosis has been made. So basically, we would use that biopsy. To also determine how much IL1RAP varies in the tumor. Uh, so basically by some kind of staining, uh, and similarly, if you have a skin disease, you can do a skin biopsy and perform a similar type of staining analysis to see if there are higher or lower levels of IL1RAP, if that becomes an important biomarker for patient selection.

Unknown 2
41:08 - 41:22

Um. Thank you. Um, and do you risk running into the same limitations as for the pancreatic cancer study for the other studies related to the optimal dose selection?

Johan
41:25 - 41:59

So Product Optimus is designed for oncology. In inflammatory diseases, you typically build in the dose-finding part already during phase two. And that's probably going to be the standard in oncology as well in the future. Uh, so we don't see that as risky. It's something we will address directly instead of having to face it when the guidelines are updated. New guidelines are implemented.

Unknown 2
42:02 - 42:16

Um, yes. A specification of that question. Uh, no. I mean, the oncology team is focused on triple-negative breast cancer and lung cancer.

Johan
42:17 - 43:00

Uh oh. Um, yes. Uh, so, I think this is going to be a discussion between us and the regulatory authorities on exactly what type of doses are needed. But in lung cancer, I definitely see that the next step is probably a Phase 2 trial. And you will most likely start with two different dose levels to address Project Optimism upfront in triple negative breast cancer. Obviously, it depends on the randomized Phase 2 results and the strength of them before you can decide exactly where to go.

Unknown 2
43:03 - 43:07

Thank you. Those were all the questions coming in from the web.

Johan
43:11 - 43:46

Um, yes. So, thanks a lot. So, uh, I'd like to thank you for your attention and for the interest in Cantargia. We, as a team at Cantargia, are focused on our goals and objectives. We're very excited about where we have taken the company to now. And we are certainly looking forward to the rest of the year and to 2025, because there is so much value in our products, and we are realizing that we are getting to a maturity level where external interest is becoming more and more significant.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…